Study of Influenza Vaccination and Use of ACE Inhibitors, ARBs, Antihistamines, and Amantadine in Hospitalized COVID-19 Patients
Led by Consorci Sanitari de Terrassa · Updated on 2026-03-25
3000
Participants Needed
1
Research Sites
161 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating whether prior influenza vaccination or treatments such as ACE inhibitors ACEI, angiotensin receptor blockers ARB, antihistamines, or amantadine affect the course of COVID-19 infection in hospitalized patients. The study is observational and aims to understand if these factors relate to better health outcomes, including reduced severity and mortality, by analyzing hospital admissions and patient evolution during the pandemic.
This study observes patients admitted to the Hospital of Terrassa starting from March 1, 2020, without performing any interventions. It compares groups of patients who were previously vaccinated against influenza or were already on treatments like ACEI, ARB, antihistamines, or amantadine. The research collects data on hospital stays, ICU needs, post-COVID symptoms, thrombosis, and survival outcomes among these groups.
Participants are monitored through their hospital records and treatment histories. Researchers assess outcomes such as length of hospital stay and final patient status survivor or non-survivor. The primary measure is hospital discharge status from March 1, 2020, while secondary measures include duration of hospitalization. No additional testing or treatment is provided during the study, and patients usual care continues as normal.
CONDITIONS
Brief Title
Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
Research Team
A
Anna Puigdellívol-Sánchez, Ph.D.
M
Mar Muñoz
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Collaborating Sponsor
Who Can Participate
All Ages
All Genders
Eligibility Criteria
You may qualify if you...
Hospital admissions at the Hospital of Terrassa from March 1, 2020 for any cause.
You will not qualify if you...
Patients from outside the reference area of the Terrassa Health Consortium are excluded for comparison purposes.
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Long-term Monitoring
Duration - From March 1, 2020 until study completion
Participants who undergo routine care are observed for hospital admissions, length of stay, and clinical outcomes related to COVID-19.
Observation based on routine healthcare data without additional visits
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Studying Amantadine or Duloxetine Added to Pregabalin to Prevent Post Mastectomy Pain Syndrome in Women Aged 18 to 65
Comparing Nasal Influenza Vaccine Given at Daycare or Healthcare for Children Aged 2 to 6 Years
AGILE Phase IIIa Platform Trial to Quickly Test Multiple COVID-19 Treatments in Adults
Study of Cardiovascular Features and Treatments Affecting Outcomes in Adults Hospitalized with COVID-19 Pneumonia
Study to Collect Virus Secretions and Blood Samples for COVID-19 and Other Respiratory Virus Research and Long-Term Health Effects
Study Comparing Immune Responses After COVID-19 Infection and Vaccination in Adults
Observational Study of COVID-19 and Long COVID-19 in Saarland with Cytokine Measurements
Study of Early Vascular Aging and Arterial Stiffness After COVID-19 Infection
Using Non-Invasive Tests at 6 and 12 Months Post-Infection
International Pregnancy Registry Studying Effects of Monoclonal Antibodies and Antiviral Drugs for COVID-19 in Pregnant Women
Study of Heart and Lung Health in Adults After COVID-19 Infection
Including ICU, Non-ICU, and Non-Hospitalized Survivors
and Comparison With People Without COVID-19
COVID-19 Pandemic Waves and 2024-2025 Winter Season in Relation to Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers and Amantadine.
Anna Puigdellívol-Sánchez, Marta Juanes-González, Ana Isabel Calderón-Valdiviezo...